Opendata, web and dolomites

iHEAR SIGNED

Gene therapy of inherited and acquired hearing loss

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iHEAR project word cloud

Explore the words cloud of the iHEAR project. It provides you a very rough idea of what is the project "iHEAR" about.

caused    transgene    employed    efficiency    demonstrated    protective    360    proof    congenital    translatability    marker    optimized    children    wp2    people    patients    vector    murine    viral    primary    mutations    otic    configurations    treat    treatment    stem    wp3    expression    hc    correct    causative    cell    models    lentiviral    inherited    editing    monogenetic    opportunity    protect    spiral    inducible    model    patient    performing    aav    ipsc    wp1    incl    generate    translatable    transfer    efficient    tools    clinically    impaired    proper    therapy    proteins    experiments    gene    promoters    constructs    million    genome    neurons    medicine    adeno    collection    sgn    mirnas    substantial    samples    human    world    ear    social    vectors    safety    600    financial    toolbox    vitro    inner    designs    strategies    receptor    hearing    lines    appropriate    acquired    cells    explored    therapeutic    burden    precision    alterations    fluorescent    perform    mouse    corrective    pluripotent    ganglion    once    genes    whom    hair    transduction    vivo   

Project "iHEAR" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙999˙500 €
 EC max contribution 1˙999˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙999˙500.00

Map

 Project objective

To address the substantial financial and social burden caused by hearing loss in 360 million people world-wide, I aim to improve hearing via gene therapy to correct inherited and protect from acquired hearing loss. In vitro experiments will establish the best vector configurations for transfer of therapeutic genes and miRNAs into inner ear hair cells (HC) and spiral ganglion neurons (SGN). The efficiency of the best-performing vector designs will then be explored in vivo using fluorescent marker proteins. Cell-type specific and inducible promoters as well as receptor-targeted vectors will be employed as a safety measure and to ensure transgene expression in HC and SGN target cells. Once efficient transduction of appropriate target cells and proper expression of therapeutic proteins are demonstrated, I will perform proof-of-concept studies in hearing loss models, incl. established mouse models, to correct (WP1) or protect (WP2) from impaired hearing. To ensure translatability of these findings, I will generate human induced pluripotent stem cells (iPSC) from patients with hearing loss (WP3), so that I can test optimized constructs in human otic cells. Moreover, I have access to a collection of well-characterized samples from over 600 hearing loss patients, including children with congenital hearing loss in whom many novel monogenetic alterations were identified. These resources provide the unique opportunity to generate a novel toolbox for the treatment of hearing loss. In addition to lentiviral and adeno-associated viral (AAV) vector delivery of corrective or protective genes to treat hearing loss, I will apply state-of-the-art genome editing tools to model and correct mutations causative for hearing loss in cell lines, primary cells from murine models, human patients and patient-derived iPSC. This work will contribute to development of clinically translatable approaches for precision medicine strategies to improve hearing loss treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IHEAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IHEAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DYMOLAMO (2018)

Dynamic Modeling of Labor Market Mobility and Human Capital Accumulation

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

ECOLBEH (2020)

The Ecology of Collective Behaviour

Read More